USPTO Issues Final Rejection of Magnolia Medical’s ‘483 Patent at Issue in Litigation

SAN DIEGO--(BUSINESS WIRE)--Kurin, Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, announced today that the US Patent and Trademark Office has issued a Final Rejection in its reexamination of claims 1 and 24 of U.S. Patent No. 10,039,483 (the ‘483 patent). Claims 1 and 24 of the ‘483 patent were asserted by Magnolia Medical against Kurin’s Lock product in a patent infringement case in Delaware Federal Court. The USPTO Examiner has rejected Magnolia’s arguments regarding patentability, and the pertinent claims of that patent now stand as rejected.

“We are pleased that the Examiner has rejected the asserted claims of the ‘483 patent,” said Bob Rogers, Inventor and CEO of Kurin, Inc. “Magnolia has tried to use this patent and subsequent litigation to create confusion in the marketplace and this action by the USPTO provides greater clarity to Kurin and other interested parties. As we have said from the onset, although this legal process is long, we are confident in our position, and will do whatever is necessary to continue to provide the market-leading Kurin family of products to our customers.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections.

About Kurin, Inc.

Kurin, Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.